Because antigen independent basal BCR signaling is often elevated in lymphoma cells6,49, we assessed the impact of PCLX-001 treatment on ligand independent BCR signaling by monitoring endogenous tyrosine phosphorylation levels in the above cell lines using an anti-phospho-tyrosine (P-Tyr) antibody (PY99). The gene discussed is BCR; the disease is lymphoma.